Orphan/fast track Leverage Salarius' FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations for Ewing sarcoma to propose partnering, licensing, or co-development deals that accelerate market access and reduce regulatory risk.

Pipeline expansion Target opportunities around seclidemstat and SP-3164 across pediatric cancers, sarcomas, and hematologic/solid tumors; present potential for collaboration in Phase 1/2 trials and expansion studies with major academic centers or CROs.

Strategic funding Capitalize on existing grant support from CPRIT and the National Pediatric Cancer Foundation to propose co-funded trials, joint grant applications, or gift-in-kind partnerships to advance Ewing-related programs.

Clinical collaboration Propose strategic clinical collaboration with leading centers (e.g., MD Anderson) for hematologic cancers and related targets to accelerate trial enrollment, data generation, and potential co-development opportunities.

Early-stage commercialization Position Salarius as a partner for early access programs and strategic marketing collaborations once pivotal data emerge, offering help with patient access, companion diagnostics consideration, and payer engagement strategies.